TPST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TPST is not a good buy right now for an impatient investor. The stock lacks Intellectia buy signals, the technical setup is not convincingly bullish (RSI ~40 and only a modest/contracting positive MACD), and fundamentals show worsening losses with essentially no revenue. While a fresh analyst upgrade with a large upside price target is supportive, near-term risk is dominated by cash-burn/dilution and binary biotech catalysts into the 2026-02-04 earnings event.
Price/Trend: Regular session was down (-3.20%) with a post-market bounce (+4.62%) to ~2.83, putting price near the pivot (2.837). Momentum: MACD histogram is positive (0.0827) but positively contracting, which often signals upside momentum is fading rather than accelerating. RSI(6) at 40.56 is neutral-to-weak (not oversold), suggesting limited immediate rebound pressure. Moving averages are converging, consistent with consolidation rather than a clean uptrend. Levels: Support S1 2.608 then S2 2.467; Resistance R1 3.067 then R2 3.208. A higher-quality long entry would typically require a decisive reclaim/hold above ~3.07 with follow-through; as-is, price is sitting at the pivot where whipsaws are common. Probabilistic trend read: pattern-based expectation shows mild next-day upside but negative bias over the next week (-3.15%), indicating near-term drift risk.
Analyst catalyst: H.C. Wainwright upgrade to Buy (2026-01-
with an $11 PT, citing the Factor Bioscience CAR-T acquisition as extending runway into 2027 and adding a clinically de-risked asset (TPST-2003).
Event catalyst: Upcoming earnings on 2026-02-04 after hours can re-rate the stock if runway/pipeline updates surprise positively.
Technical catalyst: A clean break above R1 (~3.
could trigger momentum buying toward ~3.21.
Fundamentals/cash burn: Latest quarter shows deeper losses (Net Income down -66.74% YoY; EPS down -85.15% YoY) with essentially no revenue, increasing dilution/financing risk for a micro-cap (~$13.77M).
No supportive flow signals: Hedge funds and insiders are neutral with no significant recent trend.
No recent news in the past week, so there is no fresh non-analyst catalyst to justify chasing.
Technical risk: Price is near the pivot; a failure to hold could quickly test S1 (2.
and S2 (2.467).
Latest reported quarter: 2025/Q3. Revenue was 0 (no growth base), while profitability deteriorated materially: Net Income -$3.511M (down -66.74% YoY) and EPS -0.79 (down -85.15% YoY). This points to accelerating losses rather than improving operating leverage, typical of development-stage biotech but unfavorable for near-term buy timing without a strong catalyst.
Recent trend: A notable positive change occurred on 2026-01-22 when H.C. Wainwright upgraded TPST to Buy from Neutral and set an $11 price target, driven by the Factor Bioscience CAR-T acquisition (runway extension into 2027 and expanded pipeline). Wall Street pros view (implied by this note): Pros—improved cash runway and pipeline breadth with a de-risked asset; potential market opportunity in cell therapy. Cons—execution and financing risk remain high given weak financials and micro-cap status; without near-term clinical/operational catalysts, the stock can drift or dilute despite optimistic targets.
